← Leaderboards
Daniel Edmonston
Duke University
$921,038
Attributed
$921,038
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $185.3K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$921,038 · 1
By mechanism
K23$921,038 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Eva Nozik Grayck$11,896,272
- Sean M O'Brien$12,883,796
- Sudarshan K Rajagopal$6,060,418
- Karen P Alexander$27,753,285
- William M Reichert$13,488,514
Others in their field
Other Emerging Leaders on “Functional Disorder”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Susan M Landau · University Of California Berkeley$47,252,026
- Evan Z Macosko · Broad Institute, Inc.$28,495,187
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Barbara Halina Braffett · George Washington University$22,016,904
Research focus
Functional DisorderFutureAffectBiologyAdverse EffectsExcisionBindingCardiovascular DiseasesCardiovascular SystemCareer DevelopmentCause Of DeathChronic Kidney FailureBlood VesselsClinical InvestigatorClinical TrialsCardiac Catheterization ProceduresComorbidityComplicationDialysis ProcedureDoseEchocardiographyEnd Stage Renal FailureEnrollmentGenotype
Grant awards (5)
Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)$185,157
K23 · FY2025 · HL · contact PI
Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)$185,345
K23 · FY2024 · HL · contact PI
Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)$185,229
K23 · FY2023 · HL · contact PI
Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)$180,770
K23 · FY2022 · HL · contact PI
Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)$184,537
K23 · FY2021 · HL · contact PI